Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections
Disclosed herewith is drug repurposing efforts that lead to the discovery of prior non-antibiotic drugs can be used in clinical applicable ranges to treat patients of bacterial infection. These repurposed drug can be used either alone or in combination with traditional antibiotic drugs to treat bacterial strains that may develop or already have developed drug resistance.
1. A method of using a pre-existing FDA approved non-antibiotic drug to treat a patient infected with multi-drug resistance bacterium, comprising:
screening a library, wherein the library contains a plurality of FDA approved drugs and small molecules, against ESKAPE pathogens ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter cloacae );
identifying Ebselen, Auranofin and 5-fluoro-2′-deoxyuridine (FdUrd) for their ability to reduce biofilm mass, regulate exotoxin production associated inflammatory cascade, perform intracellular bacteria killing, and protect systematic skin infection in mouse model without interfering mitochondrial protein synthesis and macromolecular synthesis in said ESKAPE pathogen infected host s to confirm their potent antimicrobial activity in an applicable clinical range of about sub-micromolar to about nanomolar concentration against a plurality of pathogens;
applying Ebselen, Auranofin or 5-fluoro-2′-deoxyuridine (FdUrd) in said applicable clinical range to the patient and wherein the application of said drugs reduces the levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1(MCP-1) in the patient.
2. The method according to claim 1 , wherein said pathogens are selected from the group consisting of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA), Streptococcus pneumoniae , vancomycin-resistant enterococcus (VRE), and vancomycin-intermediate S. aureus (VISA).
3. The method according to claim 1 , wherein said pathogens are selected from the group consisting of metallo-β-Lactamase (NDM-1), carbapenemase (KPC) resistant K. pneumonia , and colistin-resistant P. aeruginosa.
4. A method of using Ebselen, Auranofin or 5-fluoro-2′-deoxyuridine (FdUrd) for treating multi-drug resistant bacteria infection, comprising identifying a patient infected with multi-drug resistant bacteria; applying to said patient a clinical relevant dosage of Ebselen, Auranofin or 5-fluoro-2′-deoxyuridine (FdUrd), wherein said clinical relevant dosage is the minimum concentration at which 90% of said multi-drug resistant bacteria growth is inhibited (MIC90), the application of said drugs is through oral for Ebselen, and through oral or IP injection for Auranofin or 5-fluoro-2′-deoxyuridine (FdUrd), and wherein the application of said drugs reduces the levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1(MCP-1) in the patient.
5. The method according to claim 4 , wherein said multidrug resistant bacteria are gram-positive pathogens selected from the group consisting of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA), Streptococcus pneumoniae , vancomycin-resistant enterococcus (VRE), and vancomycin-intermediate S. aureus (VISA).
6. The method according to claim 4 , wherein said multidrug resistant bacteria are gram-negative pathogens selected from the group consisting of metallo-β-Lactamase (NDM-1), carbapenemase (KPC) resistant K. pneumonia , and colistin-resistant P. aeruginosa.
7. A combinational therapy to treat a patient with bacterial infection to control the development of drug-resistance, comprising applying a clinical range of the non-antibiotic drug selected from the group consisting of Ebselen, and 5-fluoro-2′-deoxyuridine (FdUrd), with a conventional antibiotic drug selected from the group consisting of linezolid, clindamycin, vancomycin, ciprofloxacin, erythromycin, rifampicin, gentamicin, mupirocin, fusidic acid, retapamulin and daptomycin to the patient, wherein the combination of said non-antibiotic drug and said conventional antibiotic drug at a minimum concentration of achieving 90% bacterial growth inhibition.
8. The combinational therapy according to claim 7 , wherein said non-antibiotic drug provides synergy to said conventional antibiotic drug.
9. A method of treating intracellular bacterial infection in a patient comprising applying a clinical range of about sub-micromolar to about nanomolar concentration of the non-antibiotic drug selected from the group consisting of Ebselen, Auranofin and 5-fluoro-2′-deoxyuridine (FdUrd) until the expression of virulence factors and the formation of toxins is suppressed, wherein said virulent factors and toxins are selected from the group consisting of α-hemolysin (hla), toxic shock syndrome toxin-1 (TSST-1), and Panton-Valentine leucocidin (PVL) and wherein the application of said drugs reduces the levels of the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemo attractant protein-1 (MCP-1) in the patient.
10. The method according to claim 4 , wherein said multidrug resistant bacteria are gram-positive pathogens selected from the group consisting of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA), Streptococcus pneumoniae , vancomycin-resistant enterococcus (VRE), and vancomycin-intermediate S. aureus (VISA).
11. The method according to claim 4 , wherein said multidrug resistant bacteria are gram-negative pathogens selected from the group consisting of metallo-β-Lactamase (NDM-1), carbapenemase (KPC) resistant K. pneumonia , and colistin-resistant P. aeruginosa.